<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="determine the frequency of human parvovirus B19 (B19V) infected individuals," exact="viral" post="loads and immunity among blood donors from Argentina, in"/>
 <result pre="blood bank at Córdoba, Argentina, in 2014. Anti-B19V IgM and" exact="viral" post="loads were determined in B19V-positive plasma samples. Seven of"/>
 <result pre="years, four of them repeat donnors and three first-time donors." exact="Viral" post="loads were &amp;lt;103 IU/mL. None had IgM and 6/7"/>
 <result pre="medium level, 5–50 IU/ml). Thus one case was classified as" exact="acute" post="infection (DNA+/IgM-/IgG-) and six as potentially persistent infections (DNA+/IgM-/IgG+)."/>
 <result pre="level, 5–50 IU/ml). Thus one case was classified as acute" exact="infection" post="(DNA+/IgM-/IgG-) and six as potentially persistent infections (DNA+/IgM-/IgG+). No"/>
 <result pre="classified as acute infection (DNA+/IgM-/IgG-) and six as potentially persistent" exact="infections" post="(DNA+/IgM-/IgG+). No coinfections with other pathogens of mandatory control"/>
 <result pre="prevalence in blood donors in Argentina, demonstrating high rates of" exact="acute" post="and persistent B19V infections and high prevalence of anti-B19V"/>
 <result pre="in Argentina, demonstrating high rates of acute and persistent B19V" exact="infections" post="and high prevalence of anti-B19V IgG in a post-epidemic"/>
 <result pre="the knowledge of B19V and blood transfusion safety. Health sciences;" exact="Infectious" post="disease; Virology; Laboratory medicine; Biomarkers; Human erythroparvovirus B19; Blood"/>
 <result pre="sciences; Infectious disease; Virology; Laboratory medicine; Biomarkers; Human erythroparvovirus B19;" exact="Blood" post="donor; Blood safety; Persistent infection; Argentina. Keywords Health sciences"/>
 <result pre="disease; Virology; Laboratory medicine; Biomarkers; Human erythroparvovirus B19; Blood donor;" exact="Blood" post="safety; Persistent infection; Argentina. Keywords Health sciences Infectious disease"/>
 <result pre="Blood donor; Blood safety; Persistent infection; Argentina. Keywords Health sciences" exact="Infectious" post="disease Virology Laboratory medicine Biomarkers Human erythroparvovirus B19 Blood"/>
 <result pre="donor; Blood safety; Persistent infection; Argentina. Keywords Health sciences Infectious" exact="disease" post="Virology Laboratory medicine Biomarkers Human erythroparvovirus B19 Blood donor"/>
 <result pre="sciences Infectious disease Virology Laboratory medicine Biomarkers Human erythroparvovirus B19" exact="Blood" post="donor Blood safety Persistent infection Argentina 1 Introduction Human"/>
 <result pre="disease Virology Laboratory medicine Biomarkers Human erythroparvovirus B19 Blood donor" exact="Blood" post="safety Persistent infection Argentina 1 Introduction Human parvovirus B19"/>
 <result pre="medicine Biomarkers Human erythroparvovirus B19 Blood donor Blood safety Persistent" exact="infection" post="Argentina 1 Introduction Human parvovirus B19 (B19V, Erythroparvovirus primate"/>
 <result pre="1 Introduction Human parvovirus B19 (B19V, Erythroparvovirus primate 1 [1])" exact="infection" post="is associated with manifestations that vary depending on the"/>
 <result pre="for erythroid progenitor cells, the high virus titer during the" exact="acute" post="phase of the infection (usually 106–107 IU/ml B19V or"/>
 <result pre="the high virus titer during the acute phase of the" exact="infection" post="(usually 106–107 IU/ml B19V or higher) and the death"/>
 <result pre="or higher) and the death of infected cells after the" exact="viral" post="cycle is complete [2, 3, 4, 5] can lead"/>
 <result pre="the death of infected cells after the viral cycle is" exact="complete" post="[2, 3, 4, 5] can lead to an acute"/>
 <result pre="is complete [2, 3, 4, 5] can lead to an" exact="acute" post="cessation of red blood-cells production causing clinical conditions related"/>
 <result pre="severe, even life-threatening [5, 6]. B19V is transmitted mainly by" exact="respiratory" post="secretions and is mostly a childhood infection [6]. It"/>
 <result pre="is transmitted mainly by respiratory secretions and is mostly a" exact="childhood" post="infection [6]. It can also be transmitted by transfusion,"/>
 <result pre="transmitted mainly by respiratory secretions and is mostly a childhood" exact="infection" post="[6]. It can also be transmitted by transfusion, since"/>
 <result pre="there is no specific questionnaire to identify or suspect an" exact="infection" post="in asymptomatic blood donors that could carry the virus"/>
 <result pre="conventional methods (detergent, extreme pH, heat, filtration) [8]. Transmission, seroconversion," exact="symptomatic" post="and asymptomatic infections have been documented in patients treated"/>
 <result pre="extreme pH, heat, filtration) [8]. Transmission, seroconversion, symptomatic and asymptomatic" exact="infections" post="have been documented in patients treated with different blood"/>
 <result pre="other hand, in some individuals, B19V may persist and the" exact="viral" post="genome remain detectable during many months at low (&amp;lt;103 IU/ml)"/>
 <result pre="donors can continue donating while carrying the virus (and potentially" exact="infectious" post="virions) in their blood [3, 16, 17]. Thus, the"/>
 <result pre="blood [3, 16, 17]. Thus, the potential risk of B19V" exact="infection" post="for blood recipients should be surveyed. B19V DNA prevalence"/>
 <result pre="among blood donors, and the concentrations determined are frequently &amp;lt;104" exact="viral" post="genome UI/ml [18, 19]. However, individuals with higher viral"/>
 <result pre="&amp;lt;104 viral genome UI/ml [18, 19]. However, individuals with higher" exact="viral" post="loads have also been detected [2, 19, 20, 21,"/>
 <result pre="seroprevalence of B19V among local blood donors. 2 Methods 2.1" exact="General" post="design and ethical considerations A retrospective, observational, cross-sectional study"/>
 <result pre="quantitative PCR and specific IgM and IgG testing to identify" exact="acute" post="and persistent infections in the study population. Taking into"/>
 <result pre="specific IgM and IgG testing to identify acute and persistent" exact="infections" post="in the study population. Taking into account that all"/>
 <result pre="considered: I. DNA-positive/IgG-negative and IgM-positive or negative accounting for ongoing" exact="acute" post="infection; II. DNA-positive/IgG-positive/IgM-positive, recent acute infection; III. DNA-positive/IgG-positive/IgM-negative was"/>
 <result pre="or negative accounting for ongoing acute infection; II. DNA-positive/IgG-positive/IgM-positive, recent" exact="acute" post="infection; III. DNA-positive/IgG-positive/IgM-negative was interpreted as long-term infection or"/>
 <result pre="DNA-positive/IgG-positive/IgM-positive, recent acute infection; III. DNA-positive/IgG-positive/IgM-negative was interpreted as long-term" exact="infection" post="or potentially persistent infection. Presence of specific IgG was"/>
 <result pre="men and women aged 18–65 years who attended Fundación Banco" exact="Central" post="de Sangre (FBCS) at Córdoba, Argentina, between July 1"/>
 <result pre="the international standard WHO/NIBSC UK EN63QG 1st International Standard 2000" exact="Parvovirus" post="B19 DNA 500,000 IU/ml (code 99/800). The qPCR assay"/>
 <result pre="IU/ml. Each sample was tested in triplicate. 2.6 Serology Ridascreen" exact="Parvovirus" post="B19 IgG and IgM (R-Biopharm) ELISA tests for quantitative"/>
 <result pre="95%CI 0.9–1.4). 3.2 Detection of B19V, quantification and estimation of" exact="acute" post="and persistent infections B19V DNA was detected in seven"/>
 <result pre="Detection of B19V, quantification and estimation of acute and persistent" exact="infections" post="B19V DNA was detected in seven of the 731"/>
 <result pre="samples (0.96%, 95%CI 0.46–1.96%). All of them also had detectable" exact="viral" post="DNA by qPCR, but concentrations under the limit of"/>
 <result pre="100–200 IU/ml, Table 1). Therefore, one donor had an ongoing" exact="acute" post="infection and the other six were classified as long-term"/>
 <result pre="IU/ml, Table 1). Therefore, one donor had an ongoing acute" exact="infection" post="and the other six were classified as long-term or"/>
 <result pre="the other six were classified as long-term or potentially persistent" exact="infections" post="(Table 1). The estimated rates of acute and long-term/persistent"/>
 <result pre="or potentially persistent infections (Table 1). The estimated rates of" exact="acute" post="and long-term/persistent infections were 1.4 and 8.2 per 1000"/>
 <result pre="infections (Table 1). The estimated rates of acute and long-term/persistent" exact="infections" post="were 1.4 and 8.2 per 1000 donors, respectively. As"/>
 <result pre="number Sex Age(years) IgG [IgG] rangeIU/ml IgM Type of B19V" exact="infection" post="Pre-transfusion screening1 Type of donor Destiny of blood components"/>
 <result pre="1Pathogens included in pre-transfusion screening tests of local blood banks:" exact="Hepatitis" post="B virus, Hepatitis C virus, HIV, HTLV, Trypanosoma cruzi,"/>
 <result pre="pre-transfusion screening tests of local blood banks: Hepatitis B virus," exact="Hepatitis" post="C virus, HIV, HTLV, Trypanosoma cruzi, Treponema pallidum, and"/>
 <result pre="pallidum, and Brucella spp. NEG: negative; POS: positive. I. ongoing" exact="acute" post="infection; III. long-term infection or potentially persistent infection. 3.3"/>
 <result pre="NEG: negative; POS: positive. I. ongoing acute infection; III. long-term" exact="infection" post="or potentially persistent infection. 3.3 Seroprevalence of B19V Among"/>
 <result pre="B. Age-range distribution of results. 4 Discussion We demonstrate B19V" exact="infection" post="by viral-DNA detection in 0.96% blood donors from Argentina,"/>
 <result pre="the primers, since the genetic diversity influences the detection of" exact="infection" post="especially when nucleic acid based techniques are used [26,"/>
 <result pre="confirmed [3], these factors can explain the high seroprevalence and" exact="viral" post="DNA frequency in our study compared to others. DNA-positive"/>
 <result pre="the virus in older donors might seem striking. However, persistent" exact="infections" post="for long periods of time, decades and possibly life-long,"/>
 <result pre="with this, in our series only one individual had ongoing" exact="acute" post="infection while the remaining six had long-term/potentially persistent infections"/>
 <result pre="this, in our series only one individual had ongoing acute" exact="infection" post="while the remaining six had long-term/potentially persistent infections (all"/>
 <result pre="ongoing acute infection while the remaining six had long-term/potentially persistent" exact="infections" post="(all of them but one with low/medium levels of"/>
 <result pre="donors, which is sound given its transmission mainly through the" exact="respiratory" post="tract (any type of donor would have a similar"/>
 <result pre="a higher prevalence of sexually transmitted and parenteral pathogens (HIV," exact="Hepatitis" post="B virus, Hepatitis C virus) has been demonstrated in"/>
 <result pre="of sexually transmitted and parenteral pathogens (HIV, Hepatitis B virus," exact="Hepatitis" post="C virus) has been demonstrated in first-time donors compared"/>
 <result pre="that recipient patients were exposed to a potential risk of" exact="infection" post="through transfusion, particularly concerning direct blood transfusion. Prevalence of"/>
 <result pre="of circulating antibodies in older adults long time after the" exact="primary" post="infection, as observed by Candotti et al. [29]. In"/>
 <result pre="Consequently, older adults could be a risk-group of reinfection, both" exact="acquired" post="in the community and by transfusion. Among the seven"/>
 <result pre="IgG (not IgM), which can be interpreted as one ongoing" exact="acute" post="infection and six long-term or potential persistent infections. Thereby,"/>
 <result pre="(not IgM), which can be interpreted as one ongoing acute" exact="infection" post="and six long-term or potential persistent infections. Thereby, local"/>
 <result pre="six long-term or potential persistent infections. Thereby, local rates of" exact="acute" post="and long-term/persistent infections found were high (1.4 and 8.2"/>
 <result pre="potential persistent infections. Thereby, local rates of acute and long-term/persistent" exact="infections" post="found were high (1.4 and 8.2 per 1,000 donors,"/>
 <result pre="Unless it is a very early stage of infection, low" exact="viral" post="load detected in donors having ongoing acute infections might"/>
 <result pre="of infection, low viral load detected in donors having ongoing" exact="acute" post="infections might not seem in agreement with what could"/>
 <result pre="infection, low viral load detected in donors having ongoing acute" exact="infections" post="might not seem in agreement with what could be"/>
 <result pre="agreement with what could be expected for this stage of" exact="infection" post="(this applies for the one case classified as acute"/>
 <result pre="of infection (this applies for the one case classified as" exact="acute" post="infection). In this regard, underestimation of viral load due"/>
 <result pre="case classified as acute infection). In this regard, underestimation of" exact="viral" post="load due to B19V genome polymorphisms leading to mismatches"/>
 <result pre="in primer binding regions is possible [26, 49]. Determination of" exact="viral" post="loads should be achieved with a different molecular target"/>
 <result pre="in many countries, although the first cases of transfusion-transmitted B19V" exact="infection" post="were reported in the 90s [7]. Since after acute"/>
 <result pre="B19V infection were reported in the 90s [7]. Since after" exact="acute" post="infection B19V DNA can remain detectable in blood for"/>
 <result pre="infection were reported in the 90s [7]. Since after acute" exact="infection" post="B19V DNA can remain detectable in blood for months"/>
 <result pre="serological screening (anti-B19V IgM is undetectable very early in the" exact="infection" post="and in persistent infections). Taking this into account, the"/>
 <result pre="conclusion, this study demonstrates the occurrence of high rates of" exact="acute" post="and long-term or persistent B19V infections, as well as"/>
 <result pre="Nacional de Córdoba (SECYT UNC Resol. 411/2018) and Fundación Banco" exact="Central" post="de Sangre de Córdoba. M. Adamo was supported by"/>
 <result pre="References 1CotmoreS.F.Agbandje-McKennaM.CanutiM.ChioriniJ.A.Eis-HubingerA.HughesJ.MietzschM.ModhaS.OgliastroM.PénzesJ.J.PintelD.J.QiuJ.Soderlund-VenermoM.TattersallP.TijssenP.ConsortiumI.R.ICTV virus taxonomy profile: parvoviridaeJ. Gen. Virol.1–22019 2JuhlD.SteppatD.GörgS.HennigH.Parvovirus B19" exact="infections" post="and blood counts in blood donorsTransfus. Med. Hemotherapy4120145259 3JuhlD.GörgS.HennigH.Persistence"/>
 <result pre="and blood counts in blood donorsTransfus. Med. Hemotherapy4120145259 3JuhlD.GörgS.HennigH.Persistence of" exact="Parvovirus" post="B19 (B19V) DNA and humoral immune response in B19V-infected"/>
 <result pre="in B19V-infected blood donorsVox Sang.107201422623224916600 4JuhlD.ÖzdemirM.DreierJ.GörgS.HenningH.Look-back study on recipients of" exact="Parvovirus" post="B19 ( B19V ) DNA-positive blood componentsVox Sang.109201530531126053938 5GanaieS.S.QiuJ.Recent"/>
 <result pre=") DNA-positive blood componentsVox Sang.109201530531126053938 5GanaieS.S.QiuJ.Recent advances in replication and" exact="infection" post="of human parvovirus B19Front. Cell. Infect. Microbiol.82018 6QiuJ.Söderlund-VenermoM.YoungN.S.Human parvovirusesClin."/>
 <result pre="industryClin. Fed. Regist.2009139 9KarraschM.SchmidtV.HammerA.HochhausA.La RoséeP.PetersenI.SauerbreiA.BaierM.SayerH.G.HermannB.Chronic persistent parvovirus B19 bone marrow" exact="infection" post="resulting in transfusion- dependent pure red cell aplasia in"/>
 <result pre="infection resulting in transfusion- dependent pure red cell aplasia in" exact="multiple myeloma" post="after allogeneic haematopoietic stem cell transplantation and severe graft"/>
 <result pre="resulting in transfusion- dependent pure red cell aplasia in multiple" exact="myeloma" post="after allogeneic haematopoietic stem cell transplantation and severe graft"/>
 <result pre="stem cell transplantation and severe graft versus host diseaseHematology222017939827311084 10NagaharuK.SugimotoY.HoshiY.YamaguchiT.ItoR.MatsubayashiK.KawakamiK.OhishiK.Persistent" exact="symptomatic" post="parvovirus B19 infection with severe thrombocytopenia transmitted by red"/>
 <result pre="and severe graft versus host diseaseHematology222017939827311084 10NagaharuK.SugimotoY.HoshiY.YamaguchiT.ItoR.MatsubayashiK.KawakamiK.OhishiK.Persistent symptomatic parvovirus B19" exact="infection" post="with severe thrombocytopenia transmitted by red blood cell transfusion"/>
 <result pre="versus host diseaseHematology222017939827311084 10NagaharuK.SugimotoY.HoshiY.YamaguchiT.ItoR.MatsubayashiK.KawakamiK.OhishiK.Persistent symptomatic parvovirus B19 infection with severe" exact="thrombocytopenia" post="transmitted by red blood cell transfusion containing low parvovirus"/>
 <result pre="StaerckeC.MonahanP.E.RechtM.ChitlurM.B.GruppoR.HooperW.C.KesslerC.KulkarniR.Manco-johnsonM.J.TrimbleS.Evidence for the continued transmission of parvovirus B19 in patients" exact="with bleeding" post="disorders treated with plasma-derivedTransfusion5320131143114423659532 12TsukadaY.YokoyamaK.IshidaA.HandaM.MoriT.KizakiM.OkamotoS.Erythroid crisis caused by parvovirus"/>
 <result pre="for the continued transmission of parvovirus B19 in patients with" exact="bleeding" post="disorders treated with plasma-derivedTransfusion5320131143114423659532 12TsukadaY.YokoyamaK.IshidaA.HandaM.MoriT.KizakiM.OkamotoS.Erythroid crisis caused by parvovirus"/>
 <result pre="red blood cell productsTransfus. Complicat.512011129136 14KishoreJ.SrivastavaM.ChoudhuryN.Serological study on parvovirus B19" exact="infection" post="in multitransfused thalassemia major patients and its transmission through"/>
 <result pre="productsTransfus. Complicat.512011129136 14KishoreJ.SrivastavaM.ChoudhuryN.Serological study on parvovirus B19 infection in multitransfused" exact="thalassemia" post="major patients and its transmission through donor units Full"/>
 <result pre="through donor units Full Text IntroductionAsian J. Transfus. Sci.5201114014321897592 15StramerS.L.HollingerF.B.KatzL.M.KleinmanS.MetzelP.S.GregoryK.R.DoddR.Y.Emerging" exact="infectious disease" post="agents and their potential threat to transfusion safetyTransfusion4920091S29S19686562 16LeeT.KleinmanS.H.WenL.MontalvoL.ToddD.S.WrightD.J.ToblerL.H.MichaelP.Distribution"/>
 <result pre="donor units Full Text IntroductionAsian J. Transfus. Sci.5201114014321897592 15StramerS.L.HollingerF.B.KatzL.M.KleinmanS.MetzelP.S.GregoryK.R.DoddR.Y.Emerging infectious" exact="disease" post="agents and their potential threat to transfusion safetyTransfusion4920091S29S19686562 16LeeT.KleinmanS.H.WenL.MontalvoL.ToddD.S.WrightD.J.ToblerL.H.MichaelP.Distribution"/>
 <result pre="blood compartments and persistence of virus in blood donorsTransfusion5120111896190821303368 17MatsukaraH.ShibataS.TaniY.ShibataH.FurutaR.Persistent" exact="infection" post="by human parvovirus B19 in qualified blood donorsTransfusion4820081036103718454740 18SlavovS.N.KashimaS.Rocha-JuniorM.C.OliveiraL.C.Silva-PintoA.C.YamamotoA.Y.CovasD.T.Frequent"/>
 <result pre="a non-metropolitan blood centre, BrazilTransfus. Med.24201413013224684574 19FrancoisK.L.ParboosingR.MoodleyP.Parvovirus B19 in South" exact="African" post="blood donorsJ. Med. Virol.9120191217122330840773 20ZadsarM.AghakhaniA.BanifazlMohammadKazemimaneshM.MortezaS.YazdiT.MamishiS.BavandA.MonaS. LarijaniRamezaniA.Seroprevalence, molecular epidemiology and"/>
 <result pre="DNA levels in Iranian blood donorsJ. Med. Virol.9020181318132229663448 21SlavovS.N.OtaguiriK.K.CovasD.T.KashimaS.Prevalence and" exact="viral" post="load of human parvovirus B19 (B19V) among blood donors"/>
 <result pre="B19 (B19V) among blood donors in South-East BrazilIndian J. Hematol." exact="Blood" post="Transfus.32201632332527408426 22SlavovS.N.RodriguesE.S.SauvageV.CaroV.DiefenbachC.F.ZimmermannA.M.CovasD.T.LapercheS.KashimaS.Parvovirus B19 seroprevalence, viral load, and genotype characterization"/>
 <result pre="in South-East BrazilIndian J. Hematol. Blood Transfus.32201632332527408426 22SlavovS.N.RodriguesE.S.SauvageV.CaroV.DiefenbachC.F.ZimmermannA.M.CovasD.T.LapercheS.KashimaS.Parvovirus B19 seroprevalence," exact="viral" post="load, and genotype characterization in volunteer blood donors from"/>
 <result pre="in patients with febrile exanthemaEpidemiol. Infect.140201245446121676356 25PedrantiM.S.Rodriguez-LombardiG.BracciaforteR.RomanoN.LujanP.RicchiB.MautinoJ.AdamoM.P.Parvovirus B19 in HIV+" exact="adult" post="patients with different CD4+ lymphocyte countsJ. Med. Microbiol.6620171715172129095139 26KoppelmanM.H.G.M.RoodI.G.H.FryerJ.F.BaylisS.a.CuypersH.T.M.Parvovirus"/>
 <result pre="ChileRev. Med. Chile139201114314921773649 29CandottiD.EtizN.ParsyanA.AllainJ.Identification and characterization of persistent human erythrovirus" exact="infection" post="in blood donor samplesJ. Virol.782004121691217815507603 30SchreiberG.KleinmanS.H.GlynnS.A.LeeT.H.ToblerL.MontalvoL.ToddD.KissJ.E.ShyamalaV.BuschM.P.Prevalence and quantitation of"/>
 <result pre="donors and correlation with specific antibodies against structural and non-structural" exact="viral" post="proteinsVox Sang.84200330030712757504 33Servant-DelmasA.MorinetF.Update of the human parvovirus B19 biologyTransfus."/>
 <result pre="variant , Bulgaria , 2004 to 2013Euro Surveill.21201618 36MorO.OfirI.PavelR.BassalR.CohenD.ShohatT.MendelsonE.Parvovirus B19V" exact="infection" post="in Israel : prevalence and occurrence of acute infection"/>
 <result pre="36MorO.OfirI.PavelR.BassalR.CohenD.ShohatT.MendelsonE.Parvovirus B19V infection in Israel : prevalence and occurrence of" exact="acute" post="infection between 2008 and 2013Epidemiol. Infect.144201620721425990962 37ZaaijerH.L.KoppelmanM.H.G.M.FarringtonC.P.Parvovirus B19 viraemia"/>
 <result pre="B19V infection in Israel : prevalence and occurrence of acute" exact="infection" post="between 2008 and 2013Epidemiol. Infect.144201620721425990962 37ZaaijerH.L.KoppelmanM.H.G.M.FarringtonC.P.Parvovirus B19 viraemia in"/>
 <result pre="40SantonjaC.Santos-BrizA.PalmedoG.KutznerH.RequenaL.Detection of human parvovirus B19 DNA in 22% of 1815" exact="cutaneous" post="biopsies of a wide variety of dermatological conditions suggests"/>
 <result pre="cutaneous biopsies of a wide variety of dermatological conditions suggests" exact="viral" post="persistence after primary infection and casts doubts on its"/>
 <result pre="a wide variety of dermatological conditions suggests viral persistence after" exact="primary" post="infection and casts doubts on its pathogenic significanceBr. J."/>
 <result pre="wide variety of dermatological conditions suggests viral persistence after primary" exact="infection" post="and casts doubts on its pathogenic significanceBr. J. Dermatol.17720171060106528196283"/>
 <result pre="parvovirus B19 persists in tonsillar B cellsNat. Commun.820171928232747 42SoderlundM.RuutuP.RuutuT.AsikainenK.FranssilaR.HedmanK.Primary and" exact="secondary" post="infections by human parvovirus B19 following bone marrow transplantation:"/>
 <result pre="B19 persists in tonsillar B cellsNat. Commun.820171928232747 42SoderlundM.RuutuP.RuutuT.AsikainenK.FranssilaR.HedmanK.Primary and secondary" exact="infections" post="by human parvovirus B19 following bone marrow transplantation: characterization"/>
 <result pre="B-cell molecular immunologyScand. J. Infect. Dis.2919971291359181647 43DorseyK.A.MoritzE.D.SteeleW.R.EderA.F.StramerS.L.A comparison of human" exact="immunodeficiency" post="virus, hepatitis C virus, hepatitis B virus, and human"/>
 <result pre="immunologyScand. J. Infect. Dis.2919971291359181647 43DorseyK.A.MoritzE.D.SteeleW.R.EderA.F.StramerS.L.A comparison of human immunodeficiency virus," exact="hepatitis" post="C virus, hepatitis B virus, and human T-lymphotropic virus"/>
 <result pre="Dis.2919971291359181647 43DorseyK.A.MoritzE.D.SteeleW.R.EderA.F.StramerS.L.A comparison of human immunodeficiency virus, hepatitis C virus," exact="hepatitis" post="B virus, and human T-lymphotropic virus marker rates for"/>
 <result pre="marker rates for directed versus volunteer blood donations to the" exact="American" post="Red Cross during 2005 to 2010Transfusion5320131250125623003320 44GaggeroA.RiveraJ.CalquínE.LarrañagaC.E.LeónO.DíazP.GaggeroN.Seroprevalencia de anticuerpos"/>
 <result pre="45SlavovS.N.HaddadS.K.Silva-pintoA.C.AmarillaA.A.AlfonsoH.L.AquinoV.H.CovasD.T.Molecular and phylogenetic analyses of human parvovirus B19 isolated from" exact="Brazilian" post="patients with sickle cell disease and b -thalassemia major"/>
 <result pre="analyses of human parvovirus B19 isolated from Brazilian patients with" exact="sickle cell disease" post="and b -thalassemia major and healthy blood donorsJ. Med."/>
 <result pre="human parvovirus B19 isolated from Brazilian patients with sickle cell" exact="disease" post="and b -thalassemia major and healthy blood donorsJ. Med."/>
 <result pre="worldEpidemiol. Infect.124200044945710982069 48PorignauxR.VuibletV.BarbeC.NguyenY.LavaudS.ToupanceO.AndreolettiL.RieuP.LevequeN.A clinically relevant, syngeneic model of spontaneous, highly" exact="metastatic" post="B16 mouse melanomaJ. Med. Virol.8520131115112123588740 49KoppelmanM.H.G.M.Van SwietenP.CuijpersH.T.M.Real-time polymerase chain"/>
 <result pre="donations using a commercial and an in-house assayTransfusion5120111346135421175647 50OrnoyA.ErgazZ.Parvovirus B19" exact="infection" post="during pregnancy and risks to the fetusBirth Defect. Res.1092017311323"/>
 <result pre="parvovirus B19-induced pure red cell aplasia in a child following" exact="heart" post="transplantCardiol. Young25201537337524555951 52WürdingerM.ModrowS.PlentzA.Impact of parvovirus B19 viremia in liver"/>
 <result pre="liver transplanted children on anemia: a retrospective studyViruses9201717 53CavalloR.MerlinoC.ReD.BolleroC.BergalloM.LemboaD.MussoaT.LeonardiG.SegoloniG.P.Nego PonziA.B19" exact="virus infection" post="in renal transplant recipientsJ. Clin. Virol.26200336136812637086"/>
 <result pre="transplanted children on anemia: a retrospective studyViruses9201717 53CavalloR.MerlinoC.ReD.BolleroC.BergalloM.LemboaD.MussoaT.LeonardiG.SegoloniG.P.Nego PonziA.B19 virus" exact="infection" post="in renal transplant recipientsJ. Clin. Virol.26200336136812637086"/>
</results>
